The following research study is being conducted in KU Integrative Medicine. If you are interested in participating, call 913-588-6104 to leave your contact information and the clinical research coordinator will contact you.
This research study will be conducted at the University of Kansas Medical Center with Jeanne Drisko, M.D., as the principal investigator. The goal of testing intravenous vitamin C is to achieve a desired good outcome at the smallest dose with minimal side effects.
It is known that people with cancer are using high doses of intravenous vitamin C as a cancer treatment and this is occurring not infrequently. When vitamin C is given in this manner, it is known that it acts like a drug and not a vitamin. It is not known how high doses of intravenous vitamin C are handled and eliminated by the body or if it is safe. This is in spite of the fact that high-dose intravenous vitamin C has been given to patients for over 30 years. No formal pharmacokinetic study has been done at these high doses.
Pharmacokinetic evaluation is a type of drug study that examines the processes of absorption, distribution, and elimination of a drug by the body determines. It determines how rapidly and for how long the drug will appear at the target location. Also, the relationship between a beneficial or toxic effect of a drug and the safety of the drug needs to be established for different concentrations.
Approximately 12 participants with cancer and approximately 21 healthy people will be enrolled and seen in the Program in Integrative Medicine Infusion Clinic.
If you are interested in participating in this study, or would like more information, please contact our clinical research coordinator at 913-588-6104.